Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab-Reference-Cited by-同舟云学术

Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab

Published:2017-05-02 Issue:12 Volume:116 Page:1526-1535
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Custodio A, ,Carmona-Bayonas A,Jiménez-Fonseca P,Sánchez M L,Viudez A,Hernández R,Cano J M,Echavarria I,Pericay C,Mangas M,Visa L,Buxo E,García T,Rodríguez Palomo A,Álvarez Manceñido F,Lacalle A,Macias I,Azkarate A,Ramchandani A,Fernández Montes A,López C,Longo F,Sánchez Bayona R,Limón M L,Díaz-Serrano A,Hurtado A,Madero R,Gómez C,Gallego J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2017122.pdf

Reference29 articles.

1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (9742): 687–697.

2. Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo MLS, Ramchandani A, Martínez EA, Custodio A, Garrido M, Echavarría I, Cano JM, Barreto JEL, García TG, Manceñido FÁ, Lacalle A, Cardona MF, Mangas M, Visa L, Buxó E, Azkarate A, Díaz-Serrano A, Montes AF, Rivera F (2016) On the effect of triplet or doublet chemotherapy in advanced gastric cancer: results from a National Cancer Registry. J Natl Compr Canc Netw 14 (11): 1379–1388.

3. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47 (11): 1245–1251.

4. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22 (12): 2395–2403.

5. Chau I, Ashley S, Cunningham D (2009) Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol 27 (19): e3–e4.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry;Clinical and Translational Oncology;2024-02-15

2. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry;Gastric Cancer;2023-11-15

3. Development and Validation of a Nomogram to Predict the Risk of Tinnitus Severity in Patients With Unilateral Subjective Tinnitus;Ear, Nose & Throat Journal;2023-09-29

4. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy;Therapeutic Advances in Medical Oncology;2023-01

5. Machine learning models for predicting one-year survival in patients with metastatic gastric cancer who experienced upfront radical gastrectomy;Frontiers in Molecular Biosciences;2022-12-01